PMVP · PMV Pharmaceuticals, Inc. · Executive Compensation
$1.27
+0.06 (+4.96%)
At close · Nov 13
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has determined that the Company's current available cash, cash equivalents and marketable securities may not be sufficient to fund its planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$95.93M
Shares
75.53M
Volume · Nov 13
290.84K
Avg daily vol (3M)
676.77K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| David H. Mack | President, Chief Executive Officer and Director | $1,665,191 |
| Robert Ticktin | General Counsel & Chief Operating Officer | $861,206 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| David H. Mack | President, Chief Executive Officer and Director | $4,760,281 |
| Deepika Jalota | Pharm.D. Chief Development Officer | $1,929,014 |
| Michael Carulli | Chief Financial Officer | $1,379,515 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| David H. Mack | President, Chief Executive Officer and Director | $2,209,795 |
| Winston Kung | Former Chief Operating Officer and Chief Financial Officer | $1,260,259 |
| Deepika Jalota | Pharm.D. Chief Development Officer | $1,097,198 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David H. Mack | President, Chief Executive Officer and Director | $3,576,440 |
| Winston Kung | Former Chief Operating Officer and Chief Financial Officer | $1,768,476 |
| Deepika Jalota | Pharm.D. Chief Development Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| David H. Mack | President, Chief Executive Officer and Director | $3,541,855 |
| Winston Kung | Chief Operating Officer and Chief Financial Officer | $1,665,259 |
| Leila Alland | Chief Medical Officer | $1,400,292 |
| Deepika Jalota | Pharm.D. Chief Regulatory and Quality Officer | $1,026,863 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Leila Alland | Chief Medical Officer | $1,674,649 |
| David H. Mack | President, Chief Executive Officer and Director | $1,314,113 |
| Winston Kung | Chief Operating Officer and Chief Financial Officer | $825,365 |
| Deepika Jalota | Pharm.D. Chief Regulatory and Quality Officer | $532,673 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| David H. Mack | President, Chief Executive Officer and Director | $628,110 |
| Winston Kung | Chief Operating Officer and Chief Financial Officer | $562,440 |
| Deepika Jalota | Pharm.D. Chief Regulatory and Quality Officer | $517,138 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Matthew Eckler | director | Appointed | 2026-10-05 |
| Leila Alland | Chief Medical Officer (“CMO”) | Resigned | 2024-01-05 |
| Winston Kung | Chief Operating Officer (“COO”) | Resigned | 2024-01-05 |
| Winston Kung | Chief Financial Officer (“CFO”) | Resigned | 2024-01-05 |
| Michael Carulli | Chief Financial Officer ("CFO"), principal financial officer and principal accounting officer | Appointed | 2024-01-05 |
| Carol Gallagher, Pharm.D. | Class I director | Appointed | 2022-11-04 |
| Thilo Schroeder, Ph.D. | member of the Board of Directors | Resigned | 2022-11-04 |
Leadership
- David H. Mack CEO, Board Member
- Michael Carulli CFO
- Robert Ticktin COO
- Arnold Levine Board Member
- Carol Gallagher Board Member
- Carol Gallagher, Pharm.D. Board Member
- Charles M. Baum Board Member
- Charles M. Baum, M.D., Ph.D. Board Member
- Continuing Directors Board Member
- Dr. Matthew Eckler Board Member
- Richard Heyman Board Member
Key facts
CIK
1699382
CUSIP
69353Y103
13F (30d)
50 filings
38 filers
Visit website
Investor relations